Citigroup Maintains Buy on Mersana Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Ashiq Mubarack maintains a Buy rating on Mersana Therapeutics but lowers the price target from $6 to $5.
August 27, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup's analyst Ashiq Mubarack maintains a Buy rating on Mersana Therapeutics but reduces the price target from $6 to $5, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in Mersana Therapeutics' potential, but the lowered price target reflects a tempered outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100